1st Part of the Guide/FAQ (Video):
WATCH the Video of Dr. Gunnar Bücker discussing various forms of Apheresis
2nd Part of the Guide/FAQ (Text):
READ the community quick guide on various forms of Apheresis used for Long Covid, Post Vac Syndrome and Chronic Illness below:
(Simply click on a topic to open it)
Help Apheresis, Immunoadsorption, Plasmapheresis (for example Rheoperesis, TPE and Inuspheresis) and EBOO/EBOO2 are the forms of apheresis that have been trialed in the last years.
The more selective the specific form of apheresis is, the better are the the results - our own reporting system has shown the same results as many polls and public sources quoting clinical experience (see here).
The most successful forms of Apheresis to treat Long Covid and Post Vac according to the data our community members have submitted is:
1. Help Apheresis (80% success rate, highly selective, several pathways)
2. EBOO/EBOO2 (20% success rate, unselective, several pathways - good for viral persistence) WARNING - do not use if you have affected veins.
3. Immunoadsorption (10-30%% success rate, highly selective, single pathway)
4. Plasmapheresis (20% success rate of Rheopheresis and other selective forms of Plasmapheresis, several pathways)
5. Inuspheresis (unselective, several pathways, trend to harm permanently) WARNING - use at your own risk!
6. TPE - Therapeutic Plasma Exchange - strong trend to harm permanently. WARNING - use at your own risk!
Available sources report a success rate of 70-80% in average, in various levels, but the majority of our community members report they got a big part of their life back through the treatment:
- ISFA World Congress (International society for apheresis) - Dr. Gunnar J. Bücker, Dr. Marcella Bürkner, Dr. Lutz Fricke and Prof. Christel Weiß presented their Help Apheresis for Long Covid treatment results during the congress: Comparison of symptoms before and after HELP shows a significant and sustained alleviation of symptoms (p < 0,0001), the overall rating increased from a score of 2 (range 1 – 3) before apheresis to 3 (1-5) after apheresis and to 4 (1.2-5) currently and 83% of patients would recommend the treatment after they have been treated
- Eureka Health Poll - 35.000 treatment reports for Long Covid. H.E.L.P. Apheresis came in 1st position of successful treatments that improved patrients significantly:
- Patient groups - over 75% of patients have benefited in various degrees in polls of patient groups like 'Larnaca Helpers' on Facebook
- Treating Doctors Socials - Dr Gunnar Bücker on his twitter channel reports success rates of 60-80% https://mobile.twitter.com/buckergunnar
- Treating doctors in the Media - Dr Ringel reports success rates of 70% in the media:
- Treating doctors in the Media - Dr Linkesch reports success rates of 90% in the media:
- Dr Beate Jaeger in her observations reports success rates of 70-90%:
1) Help Apheresis is very efficient and recommended as first-line treatment
2) Immunoadsorption can give additional benefits for those with high autoantibody levels (before or after Help Apheresis)
3) Plasmapheresis works to a certain degree, but by far not at the level of Help Apheresis - the more selective the specific form of Plasmapheresis is, the better results are
4) EBOO/EBOO2 can give additional results if viral persistence is an issue - but with weak veins it has a tendency to worsen patients
5) TPE (Therapeutic Plasma Exchange) and Inuspheresis seem to be very invasive. Whilst there were some results observed in some patients, for many it caused a permanent worsening of their condition
Help Apheresis: Yes: 80% success rate in clinical experience/reports and in 2 independent scientific studies
Immunoadsorption: No: 0% success in one study, 10-30% in clinical experience/reports
Plasmapheresis: No conclusive data yet, but much less efficient than Help Apheresis- only selective versions of Plasmapheresis seem to show at least some results
TPE: No - ME/CFS communities have been warning since decades, but some publications still claim there is no risks
Inuspheresis: A single study of the commercial company (founded by alternative practitioners/healers) that produces the Inus systems claims an efficiency of 74% and more. Community member reports show a tendency to permanently worsen patients as the filtration is unselective and possibly too invasive
Find all studies on vorious forms of apheresis click here to see
We have listed a comparison of apheresis types used for Long Covid, Post Vac Syndrome and Chronic Illness below. Important: Use the colour codes on the bottom for easier comparison.
1 Ali et al. 2008, Heparin-induced Extracorporeal Lipoprotein Precipitation (HELP) Therapy for Dry AMD. Retina Today, 9/10: 72-75
2 Armstrong, VW 1994. Die säureinduzierte Präzipitation von Low-Density-Lipoprotein mit Heparin: Grundlagen zum H.E.L.P.-Verfahren. Bibliomed, Med.Verl.-Ges (zugleich Göttingen, Univ., Habli.-Schr., 1987); ISBN: 3-921958-99-7.)
3 Bianchin, G et al., Role of H.E.L.P.-apheresis in the treatment of sudden sensorineural hearing loss in a group of 230 patients. Acta Otorhinolaryngol Ital 2011; 31:395-398.
4 Bianchin, G et al., Treatment with HELP-Apheresis in patients suffering from sudden sensorineural hearing loss: A prospective, randomized, controlled study. Laryngoscope. 2010; 120(4):800-7.
5 Buuren, van F et al 2012, HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures. Clin Res Cardiol Suppl 7:24–30
6 Canis, M et al., Fibrinogen/LDL apheresis is a promising rescue therapy for sudden sensorineural hearing loss. Clin Res Cardiol Suppl (2012) 7:36–40.
7 Dittrich-Riediger J, et al., Adverse events of lipoprotein apheresis and immunoadsorption at the Apheresis Center at the University Hospital Dresden. Atherosclerosis Supplements 18, (2015) 45-52.
8 G-BA Beschluss vom 19.08.2008
9 Hagemeyer B D., Fibrinogen- und LDL-Apherese zur Behandlung des akuten Hörsturzes im Vergleich zur Standardtherapie nach Stennert.(2013); nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-132656
10 Heigl et al 2015, Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Atherosclerosis Supplements 18 154-162.
11 Jaeger, BR et al., Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. nature clinical practice cardiovascular medicine march 2009 vol 6 no 3
12 KBV Qualitätsberichte 2012-2016 (Berichtszeiträume 2011-2015)
13 Kleophas W et al., [Acute effects of extracorporeal LDL cholesterol and fibrinogen elimination on blood rheology and microcirculation]. Dtsch Med Wochenschr. 1990 Jan 5;115(1):3-7.
14 Lane et al. 1995, Selective removal of plasma low density lipoprotein with the HELP system: biweekly versus weekly therapy, Atherosclerosis1 14( 1995)2 03-211
15 Mellwig, KP et al., Myocardial perfusion under H.E.L.P. apheresis measured by positron emission tomography. Z Kardiol 2003 (92); Suppl 3, III/30-III/37.
16 Mellwig, KP et al., Heparin-induced Extracorporeal Low density Lipoprotein Precipitation. Therapeutic Apheresis and Dialysis 2003; 7 (3): 365-369.
17 Mellwig, KP et al., Improved Coronary Vasodilatatory Capacity by H.E.L.P Apheresis: Comparing Initial and Chronic Treatment. Therapeutic Apheresis and Dialysis 2006; 10 (6): 510-517.
18 Moriarty et al. 2001, C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158, 495-498
19 Moriarty, PM et al., Effect of Low-Density Lipoprotein Cholesterol Apheresis on Blood Viscosity. The American Journal of Cardiology 2004, 93:1044-46.
20 Nordestgaard et al. 2010, Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 31, 2844–2853
21 Roeseler E, et al., Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease -Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization. Arterioscler Thromb Vasc Biol. 2016; 36: 2019-2027.
22 Schettler et al. 2017, The German Lipoprotein Apheresis Registry (GLAR) - almost 5 years on. Clin Res Cardiol Suppl.2017 Mar;12 (Suppl1):44-49
23 Schuff-Werner, P. Clinical long-term results of H.E.L.P-apheresis. Z Kardiol 2003 (92): Suppl 3, III/28-III/29.
24 Schuff-Werner, P. Untersuchungen zur hämorheologischen Wirksamkeit der LDL-Apherese. Bibliomed, Medizinische Verlagsgesellschaft mbH, Melsungen 1993.
25 Schulz & Schlüter 2017, PCSK9 targets important for lipid metabolism. Clin Res Cardiol Suppl 12:2-11
26 Stefanutti, C et al., Italian Multicenter Study on Low-Density Lipoprotein Apheresis Working Group 2009 Survey. Therapeutic Apheresis and Dialysis 2013; 17(2):169–178.
27 Suckfuell 2002, Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicenter trial. Lancet; 360: 1811-17
28 Walzl et al 1998, Effects of ameliorated haemorheology on clinical symptoms in cerebrovascular disease. Atherosclerosis 139 (1998) 385-389.
29 Zanetti et al 2014, HELP LDL apheresis reduces plasma pentraxin 3 in familial hypercholesterolemia. PLoS ONE 9(7): e101290.
In addition to the above sources, we have completed the table with publicly available data published by treating clinicians (socials, media) and corrections by community members.
Found an error? Please email us, so we can keep the information up to date and correct.
Get on our community list to receive notifications about available treatment slots, latest updates and news first - expert interviews, research updates, patient and clinician insights and more. It's free! (all our services are free, we are community built by volunteers/members for members):
All the Information and Help you need:
Get on our community list to receive notifications about available treatment slots, latest updates and news first - expert interviews, research updates, patient and clinician insights and more. It's free!
(All our services are free, we are community built by volunteers/members for members)